ArticleInternational archives of allergy and immunology2026
Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in China.
Article in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAn international treat-to-target (T2T) consensus for atopic dermatitis (AD), encompassing clinical and patient-reported outcomes, was proposed in 2021. A revised framework of systemic drug therapy for moderate-to-severe AD was proposed by Zhao and Gao in 2022. This study aimed to evaluate the efficacy of abrocitinib and dupilumab in patients with moderate-to-severe AD in the context of the clinical and patient-reported T2T goals for AD proposed by Zhao and Gao.
methodsData were evaluated from adults with moderate-to-severe AD who received abrocitinib (200 mg/day) or dupilumab (300 mg biweekly after a 600 mg of loading dose) for 16 weeks in JADE COMPARE and 26 weeks in DARE. Data from patients who received abrocitinib 100 mg/day in JADE COMPARE were also included in this analysis. Assessments included the proportions of patients attaining 1-year T2T goals proposed by Zhao and Gao (Peak Pruritus Numerical Rating Scale score of ≤4, ≥75% improvement in Eczema Area and Severity Index [EASI] or EASI ≤7, ≥75% improvement in SCORing Atopic Dermatitis [SCORAD] or SCORAD ≤24, Patient-Oriented Eczema Measure score of ≤7, and Dermatology Life Quality Index score of ≤5 at week 16 of JADE COMPARE and week 26 of DARE).
resultsIn JADE COMPARE, 226, 238, and 242 patients received abrocitinib 200 mg, abrocitinib 100 mg, and dupilumab, respectively. In JADE DARE, 362 received abrocitinib 200 mg and 365 received dupilumab. The proportions of patients attaining the 1-year T2T goals at week 16 of JADE COMPARE were 41.2% (200 mg), 29.5% (100 mg), and 29.0% (dupilumab); these proportions were 49.5% (200 mg) and 38.3% (dupilumab) at week 26 of DARE.
conclusionsGreater proportions of patients attained the 1-year T2T improvements proposed by Zhao and Gao with abrocitinib 200 mg than with dupilumab. Early achievement of 1-year targets in many patients treated with abrocitinib suggests that target domains may necessitate re-evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.